FDARegulatory IntelligenceRegulation
21 CFR Part 226

Current Good Manufacturing Practice for Type A Medicated Articles

The FDA (Center for Veterinary Medicine) cGMP for Type A medicated articles — the concentrated drug premixes used to manufacture medicated feeds. It sets controls on components, potency/assay, equipment, and records so the active drug is present at the correct concentration and free of unintended carryover.

LAST REVISED
April 1986
PRODUCT AREAS
Veterinary
SCOPE & APPLICABILITY

Manufacturers of Type A medicated articles (concentrated new-animal-drug premixes) intended for use in making medicated feeds; enforced by FDA CVM under the FD&C Act.

KEY REQUIREMENTS
  • 01Control and verify incoming components used in Type A medicated articles
  • 02Assay the active drug to confirm correct potency
  • 03Prevent cross-contamination and carryover between products
  • 04Maintain complete manufacturing and control records
IMPLEMENTATION TIPS
Treat potency assay as the release-critical test — downstream feeds inherit any error
Validate cleanout/sequencing between products to control carryover
Keep component and batch records reconcilable for CVM inspection
REVISION NOTES

Long-standing FDA CVM cGMP; applied alongside Part 225 for medicated feeds. (Specific section numbers are intentionally not reproduced pending confirmation against primary text.)

21 CFR Part 226: frequently asked questions

Quick answers to common questions about 21 CFR Part 226.

What is 21 CFR Part 226?

21 CFR Part 226 — Current Good Manufacturing Practice for Type A Medicated Articles — is a regulation issued by the Food and Drug Administration (United States). The FDA (Center for Veterinary Medicine) cGMP for Type A medicated articles — the concentrated drug premixes used to manufacture medicated feeds. It sets controls on components, potency/assay, equipment, and records so the active drug is present at the correct concentration and free of unintended carryover.

Who does 21 CFR Part 226 apply to?

Manufacturers of Type A medicated articles (concentrated new-animal-drug premixes) intended for use in making medicated feeds; enforced by FDA CVM under the FD&C Act.

What are the key requirements of 21 CFR Part 226?

FDA 21 CFR Part 226 requires, among other things: Control and verify incoming components used in Type A medicated articles; Assay the active drug to confirm correct potency; Prevent cross-contamination and carryover between products; Maintain complete manufacturing and control records.

When was 21 CFR Part 226 last updated?

The current version of 21 CFR Part 226 dates from April 1986. Long-standing FDA CVM cGMP; applied alongside Part 225 for medicated feeds. (Specific section numbers are intentionally not reproduced pending confirmation against primary text.).

RELATED STANDARDS
RELATED FDA RECALLS
where Documentation & Change Control control fails
See all Documentation & Change Control recalls →

Live openFDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.

THIS STANDARD IN PRACTICE

Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.

Weekly Briefing

Track the standards that move

When 21 CFR Part 226 — or any GxP requirement — is revised, recalled against, or clarified by new guidance, the Weekly GxP Briefing surfaces it. Free, one email a week.

Read a past issue →